Skip to content
Medium cut-off hemodialysis in multiple myeloma-associated cast nephropathy: A single-center experience
All contributors

Onconephrology contributor

Pazdur, Richard

Primarily Anti-VEGF / TKI renal effects#34 of 47 recognized
  • #2 in Anti-VEGF / TKI renal effects
10
Clinical papers
1,824
Citations (iCite)
0 / 9
First / senior author
2003–2021
Active years

Output over time

Clinical corpus papers per year — peak 2 in 2007.

  • 2003: 1 paper
  • 2007: 2 papers
  • 2009: 1 paper
  • 2010: 1 paper
  • 2013: 1 paper
  • 2015: 1 paper
  • 2017: 1 paper
  • 2021: 2 papers
20032021

Subfield mix

Clinical papers by onconephrology subfield (a paper can count in more than one).

Anti-VEGF / TKI renal effects7
Myeloma cast nephropathy2
Anticancer drug nephrotoxicity1
Checkpoint-inhibitor kidney injury1

Agents they study

Catalog agents whose clinical kidney literature lists Pazdur among the leading contributors.

Sorafenib2

Verify

Representative recent papers, and this author’s full PubMed bibliography.

PMID 33139264 (opens PubMed in a new tab)PMID 33044793 (opens PubMed in a new tab)PMID 28232599 (opens PubMed in a new tab)PMID 26324740 (opens PubMed in a new tab)PMID 23775332 (opens PubMed in a new tab)PMID 20061402 (opens PubMed in a new tab)All papers on PubMed

A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,329-article corpus (regenerated 2026-08-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.